Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec;30(1):2327367.
doi: 10.1080/13814788.2024.2327367. Epub 2024 Mar 18.

Biomarkers for predicting atrial fibrillation: An explorative sub-analysis of the randomised SCREEN-AF trial

Katharina Schmalstieg-Bahr  1   2 , David J Gladstone  3   4 , Eva Hummers  2   5 , Johanna Suerbaum  5   6 , Jeff S Healey  7 , Antonia Zapf  8 , Denise Köster  8 , Stefanie M Werhahn  6 , Rolf Wachter  5   6   9
Affiliations

Biomarkers for predicting atrial fibrillation: An explorative sub-analysis of the randomised SCREEN-AF trial

Katharina Schmalstieg-Bahr et al. Eur J Gen Pract. 2024 Dec.

Abstract

Background: Atrial fibrillation (AF) is a common treatable risk factor for stroke. Screening for paroxysmal AF in general practice is difficult, but biomarkers might help improve screening strategies.

Objectives: We investigated six blood biomarkers for predicting paroxysmal AF in general practice.

Methods: This was a pre-specified sub-study of the SCREEN-AF RCT done in Germany. Between 12/2017-03/2019, we enrolled ambulatory individuals aged 75 years or older with a history of hypertension but without known AF. Participants in the intervention group received active AF screening with a wearable patch, continuous ECG monitoring for 2x2 weeks and usual care in the control group. The primary endpoint was ECG-confirmed AF within six months after randomisation. High-sensitive Troponin I (hsTnI), brain natriuretic peptide (BNP), N-terminal pro-B-type natriuretic peptide (NT-pro BNP), N-terminal pro atrial natriuretic peptide (NT-ANP), mid-regional pro atrial natriuretic peptide (MR-pro ANP) and C-reactive protein (CRP) plasma levels were investigated at randomisation for predicting AF within six months after randomisation.

Results: Blood samples were available for 291 of 301 (96.7%) participants, including 8 with AF (3%). Five biomarkers showed higher median results in AF-patients: BNP 78 vs. 41 ng/L (p = 0.012), NT-pro BNP 273 vs. 186 ng/L (p = 0.029), NT-proANP 4.4 vs. 3.5 nmol/L (p = 0.027), MR-pro ANP 164 vs. 125 pmol/L (p = 0.016) and hsTnI 7.4 vs. 3.9 ng/L (p = 0.012). CRP levels were not different between groups (2.8 vs 1.9 mg/L, p = 0.1706).

Conclusion: Natriuretic peptide levels and hsTnI are higher in patients with AF than without and may help select patients for AF screening, but larger trials are needed.

Keywords: Atrial fibrillation; ClinicalTrials.gov Identifier: NCT02392754; natriuretic peptides; prediction; primary care; screening; www.DZHK.de: SCREEN-AF DZHK15.

Plain language summary

BNP, NT-pro BNP, NT-ANP and MR-pro ANP and hsTnI levels are higher in patients with AF than without AFWith a sensitivity at 100%, BNP had the highest specificity of 60% (BNP level 50.1ng/L), followed by NT-pro BNP with a specificity of 53% (179ng/l).

PubMed Disclaimer

Conflict of interest statement

JH has research grants and speaking fees from Medtronic, Boston Scientific, BMS/Pfizer, Servier and consulting fees from Bayer. DG reported receiving an operating grant from the Canadian Stroke Prevention Intervention Network (C-SPIN) during the conduct of the main SCREEN-AF trial (C-SPIN is a peer-reviewed national network grant funded by the Canadian Institutes of Health Research [CIHR]). He was supported by a Mid-Career Investigator Award from the Heart and Stroke Foundation (Canada) and the Department of Medicine and Bastable-Potts Chair at Sunnybrook Health Sciences Centre, Toronto. He serves as a Canadian national co-leader for the ARCADIA trial. He received an honorarium for participation in ad hoc advisory board for HLS Therapeutics Inc. He has had no personal financial relationships with cardiac monitoring device manufacturers or pharmaceutical companies related to AF in the past 6+ years. RW reports receiving grants from Deutsches Zentrum für Herz-/Kreislaufforschung for the conduct of the study, Deutsche Forschungsgemeinschaft, European Union, Bundesministerium für Bildung und Forschung, Boehringer Ingelheim and Medtronic; personal fees from AstraZeneca, Bayer, Boehringer Ingelheim, CVRx, Daiichi-Sankyo, BMS, Medtronic, Novartis, Pfizer, Pharmacosmos, sciarc and Servier outside the submitted work.

Figures

Figure 1.
Figure 1.
Flow diagram SCREEN-AF sub-trial (*1 withdrew consent for biomarker analysis, 3 did not give consent for biomarker analysis, 6 blood samples not available).
Figure 2.
Figure 2.
ROC curves of different biomarkers to identify patients developing atrial fibrillation (patients included n = 291).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Riley AB, Manning WJ.. Atrial fibrillation: an epidemic in the elderly. Expert Rev Cardiovasc Ther. 2011;9(8):1–8. doi: 10.1586/erc.11.107. - DOI - PubMed
    1. Weng L-C, Preis SR, Hulme OL, et al. . Genetic predisposition, clinical risk factor burden, and lifetime risk of atrial fibrillation. Circulation. 2018;137(10):1027–1038. doi: 10.1161/CIRCULATIONAHA.117.031431. - DOI - PMC - PubMed
    1. Borowsky LH, Regan S, Chang Y, et al. . First diagnosis of atrial fibrillation at the time of stroke. Cerebrovasc Dis. 2017;43(3-4):192–199. doi: 10.1159/000457809. - DOI - PubMed
    1. Sposato LA, Cipriano LE, Saposnik G, et al. . Diagnosis of atrial fibrillation after stroke and transient ischaemic attack: a systematic review and meta-analysis. Lancet Neurol. 2015;14(4):377–387. doi: 10.1016/S1474-4422(15)70027-X. - DOI - PubMed
    1. Hindricks G, Potpara T, Dagres N, et al. . 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2020;42(5):373–498. doi: 10.1093/eurheartj/ehaa612. - DOI - PubMed